These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10777 related articles for article (PubMed ID: 15693645)
21. Staging of regional nodes in AJCC stage I and II melanoma: 18FDG PET imaging versus sentinel node detection. Belhocine T; Pierard G; De Labrassinne M; Lahaye T; Rigo P Oncologist; 2002; 7(4):271-8. PubMed ID: 12185291 [TBL] [Abstract][Full Text] [Related]
22. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Strobel K; Dummer R; Husarik DB; Pérez Lago M; Hany TF; Steinert HC Radiology; 2007 Aug; 244(2):566-74. PubMed ID: 17641374 [TBL] [Abstract][Full Text] [Related]
23. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. Crippa F; Leutner M; Belli F; Gallino F; Greco M; Pilotti S; Cascinelli N; Bombardieri E J Nucl Med; 2000 Sep; 41(9):1491-4. PubMed ID: 10994727 [TBL] [Abstract][Full Text] [Related]
24. Sentinel lymph node excision and PET-CT in the initial stage of malignant melanoma: a retrospective analysis of 61 patients with malignant melanoma in American Joint Committee on Cancer stages I and II. Klode J; Dissemond J; Grabbe S; Hillen U; Poeppel T; Boeing C Dermatol Surg; 2010 Apr; 36(4):439-45. PubMed ID: 20187901 [TBL] [Abstract][Full Text] [Related]
25. Preoperative 18F-FDG-PET/CT imaging and sentinel node biopsy in the detection of regional lymph node metastases in malignant melanoma. Singh B; Ezziddin S; Palmedo H; Reinhardt M; Strunk H; Tüting T; Biersack HJ; Ahmadzadehfar H Melanoma Res; 2008 Oct; 18(5):346-52. PubMed ID: 18781133 [TBL] [Abstract][Full Text] [Related]
29. Combination of FDG PET/CT and contrast-enhanced MSCT in detecting lymph node metastasis of esophageal cancer. Tan R; Yao SZ; Huang ZQ; Li J; Li X; Tan HH; Liu QW Asian Pac J Cancer Prev; 2014; 15(18):7719-24. PubMed ID: 25292052 [TBL] [Abstract][Full Text] [Related]
30. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eigtved A; Andersson AP; Dahlstrøm K; Rabøl A; Jensen M; Holm S; Sørensen SS; Drzewiecki KT; Højgaard L; Friberg L Eur J Nucl Med; 2000 Jan; 27(1):70-5. PubMed ID: 10654150 [TBL] [Abstract][Full Text] [Related]
31. The role of FDG-PET-CT is limited in initial staging of nodal metastasis for thin cutaneous melanoma. Cheng D; McNicoll CF; Kirgan D; Jones MS; Rivera MR; Doyle GM; De Guzman MD; Baynosa J; St Hill CR Am J Surg; 2021 Apr; 221(4):737-740. PubMed ID: 32354604 [TBL] [Abstract][Full Text] [Related]
32. Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma. Diagnostic comparison with conventional imaging methods. Krug B; Dietlein M; Groth W; Stützer H; Psaras T; Gossmann A; Scheidhauer K; Schicha H; Lackner K Acta Radiol; 2000 Sep; 41(5):446-52. PubMed ID: 11016764 [TBL] [Abstract][Full Text] [Related]
33. Capsule endoscopy versus positron emission tomography for detection of small-bowel metastatic melanoma: a pilot study. Prakoso E; Fulham M; Thompson JF; Selby WS Gastrointest Endosc; 2011 Apr; 73(4):750-6. PubMed ID: 21288518 [TBL] [Abstract][Full Text] [Related]
34. [The role of preoperative (18)F-FDG PET-CT in lymphatic metastasis diagnosis of cutaneous malignant melanoma on extremities and trunk]. Zhang XX; Fang Y; Xu LB; Xu SF; Zhao ZG; Sun C; Ma PQ; Liu T; Yu SJ; Zhang WJ Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):372-378. PubMed ID: 29860765 [No Abstract] [Full Text] [Related]
35. No benefit in staging fluorodeoxyglucose-positron emission tomography in clinically node-negative head and neck cutaneous melanoma. Bikhchandani J; Wood J; Richards AT; Smith RB Head Neck; 2014 Sep; 36(9):1313-6. PubMed ID: 23956077 [TBL] [Abstract][Full Text] [Related]
36. Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. Macfarlane DJ; Sondak V; Johnson T; Wahl RL J Clin Oncol; 1998 May; 16(5):1770-6. PubMed ID: 9586890 [TBL] [Abstract][Full Text] [Related]
38. Value of tumour marker S-100B in melanoma patients: a comparison to 18F-FDG PET and clinical data. Reinhardt MJ; Kensy J; Frohmann JP; Willkomm P; Reinhold U; Grünwald F; Biersack HJ; Bender H Nuklearmedizin; 2002 Jun; 41(3):143-7. PubMed ID: 12109034 [TBL] [Abstract][Full Text] [Related]
39. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Schirrmeister H; Kühn T; Guhlmann A; Santjohanser C; Hörster T; Nüssle K; Koretz K; Glatting G; Rieber A; Kreienberg R; Buck AC; Reske SN Eur J Nucl Med; 2001 Mar; 28(3):351-8. PubMed ID: 11315604 [TBL] [Abstract][Full Text] [Related]
40. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. Reinhardt MJ; Joe AY; Jaeger U; Huber A; Matthies A; Bucerius J; Roedel R; Strunk H; Bieber T; Biersack HJ; Tüting T J Clin Oncol; 2006 Mar; 24(7):1178-87. PubMed ID: 16505438 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]